Samsung’s Investment Arm Eyes Exo in $100M Funding Round
Samsung’s venture capital division is reportedly in talks to invest up to $100 million in Exo, a California-based medical imaging startup, according to a Bloomberg report citing anonymous sources. The funding round is being led by prominent investors, including Sands Capital, Bold Capital, and Qubit Health Capital. Notably, Omar Ishrak, Chairman of Qubit Health Capital, is expected to join Exo’s board.
What Does Exo Do?
Founded in 2015, Exo specializes in handheld ultrasound devices that integrate AI, advanced medical imaging, and silicon chip technology. Their portable device connects to a smartphone, allowing healthcare professionals to perform scans (such as lung ultrasounds or echocardiograms) and instantly share reports via a dedicated app.
Exo’s Funding and Growth
Exo has already secured over $320 million from top investors, including:
- RA Capital Management
- BlackRock
- Intel
- Sony
- Avidity Partners
In 2021, the company raised $220 million in a Series C round, signaling strong investor confidence in its technology.
Potential Samsung Partnership
Exo is also in discussions with Samsung Medison Co., a subsidiary specializing in ultrasound diagnostics and digital X-ray systems. A collaboration could accelerate the adoption of Exo’s portable imaging solutions in global healthcare markets.
Why This Matters
- Portable & AI-Powered: Exo’s smartphone-compatible ultrasound could revolutionize point-of-care diagnostics, especially in remote areas.
- Big-Player Backing: Samsung’s potential investment highlights the growing demand for next-gen medical imaging tech.
- Market Expansion: A partnership with Samsung Medison could enhance Exo’s distribution and R&D capabilities.
No official comments have been released yet by Exo, Samsung, or the involved investment firms.
